Janus Henderson Investors US’s Pacira BioSciences PCRX Stock Holding History

Janus Henderson Investors US’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-671,287	Closed	-$51.5M	–	1192
2015 Q4	$51.5M	Sell	671,287 -238,471	-26%	-$13.5M	0.04%	409
2015 Q3	$37.4M	Sell	909,758 -2,376,712	-72%	-$146M	0.03%	481
2015 Q2	$232M	Buy	3,286,470 +1,569,892	+91%	+$124M	0.19%	137
2015 Q1	$153M	Buy	1,716,578 +565,376	+49%	+$57.4M	0.13%	222
2014 Q4	$102M	Buy	1,151,202 +145,347	+14%	+$13.7M	0.09%	296
2014 Q3	$97.5M	Buy	1,005,855 +85,758	+9%	+$8.34M	0.09%	277
2014 Q2	$84.5M	Buy	+920,097	New	+$70.1M	0.08%	309

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Janus Henderson Investors US's PCRX Position: Q1 2016 in Review

Janus Henderson Investors US sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 671,287 shares — an estimated $51.5M sold.

Janus Henderson Investors US first reported a position in PCRX in Q2 2014 and held it in 7 quarters. The position peaked at $232M in Q2 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

Janus Henderson Investors US reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
Janus Henderson Investors US sold 671,287 Pacira BioSciences shares in Q1 2016, an estimated $51.5M.
Janus Henderson Investors US first reported a position in Pacira BioSciences in Q2 2014 and held it in 7 quarters.
Janus Henderson Investors US's Pacira BioSciences position peaked at $232M in Q2 2015.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Janus Henderson Investors US's 13F filing for Q1 2016, filed 16 May 2016.